A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.

@article{Edwards1983APR,
  title={A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.},
  author={Creighton L. Edwards and Jay Herson and David M. Gershenson and Larry J. Copeland and J. Taylor Wharton},
  journal={Gynecologic oncology},
  year={1983},
  volume={15 2},
  pages={261-77}
}
From May 1978 until November 1980, 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine, Adriamycin, and cyclophosphamide (HAC) to a combination of melphalan and cis-platinum. Eleven patients were excluded from analysis and another 5 patients were excluded from response analysis. Of 153 patients evaluable for response, there were 47, or 30.7%, complete responders (all… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
Hematologic toxicity was greater in the melphalan - platinum group .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
The response rate for the HAC group was 31% and for the melphalan - platinum group was 37.8% .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
Hematologic toxicity was greater in the melphalan - platinum group .
The response rate for the HAC group was 31% and for the melphalan - platinum group was 37.8% .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
ovarian neoplasmMay be treated byCisplatin
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
ovarian neoplasmMay be treated byMelphalan
A prospective randomized clinical trial of melphalan and cis - platinum versus hexamethylmelamine , adriamycin , and cyclophosphamide in advanced ovarian cancer .
From May 1978 until November 1980 , 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine , Adriamycin , and cyclophosphamide ( HAC ) to a combination of melphalan and cis - platinum .
All Topics